

Product datasheet for **TL308638V**

TRIOBP Human shRNA Lentiviral Particle (Locus ID 11078)

Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	TRIOBP Human shRNA Lentiviral Particle (Locus ID 11078)
Locus ID:	11078
Synonyms:	DFNB28; dj37E16.4; HRIHFB2122; TAP68; TARA
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	TRIOBP - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 ⁷ TU/ml.
RefSeq:	NM_001039141 , NM_007032 , NM_138632 , NM_001039141.1 , NM_001039141.2 , NM_007032.1 , NM_007032.2 , NM_007032.3 , NM_007032.4 , NM_007032.5 , NM_138632.1 , NM_138632.2 , BC003618 , BC004303 , BC013278 , BC022200 , BM682463 , NM_001039141.3
UniProt ID:	Q9H2D6
Summary:	This gene encodes a protein with an N-terminal pleckstrin homology domain and a C-terminal coiled-coil region. The protein interacts with trio, which is involved with neural tissue development and controlling actin cytoskeleton organization, cell motility and cell growth. The protein also associates with F-actin and stabilizes F-actin structures. Mutations in this gene have been associated with a form of autosomal recessive nonsyndromic deafness. Multiple alternatively spliced transcript variants that would encode different isoforms have been found for this gene, however some transcripts may be subject to nonsense-mediated decay (NMD). [provided by RefSeq, Nov 2008]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).